From the first notice of claim to the last gasp of a confirmed plan, mass-tort bankruptcies are where coverage law gets tested—and sometimes torched. Discover how to stay ahead of the fire. Read...
Lenders typically require an opinion from borrower’s counsel in connection with a financing transaction. Review this resource kit for an overview of the process of drafting and delivering legal opinions...
Time is fleeting—by definition. Before you know it, antitrust claims can become stale. And antitrust statutes of limitations (SOLs) may bar them as a matter of law. As a litigator, whether for plaintiff...
As of July 2025, 38 U.S. states and the District of Columbia have legalized sports betting in some form—either online, in-person, or both. This expansion follows the Supreme Court's 2018 decision...
Building decarbonization and energy efficiency initiatives are spreading across the country, driven by both governmental regulatory mandates and private sector goals aimed at monitoring and reducing greenhouse...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
In The Williams Companies, Inc. v. Wolosky, the Delaware Supreme Court affirmed the Delaware Chancery Court’s ruling, in favor of stockholders, that the board of The Williams Companies failed to demonstrate that its adoption of a so-called “poison pill” was a reasonable response to a specific stockholder activist threat. The Williams Companies board adopted the disputed shareholder rights plan at the outset of the COVID-19 pandemic in response to volatile energy prices and uncertainties caused by the pandemic. The unprecedented plan included extreme features, including a 5% trigger and a broad “acting in concert” provision. Check out this article discussing the Delaware Chancery Court’s opinion.
READ NOW »
Related Content
Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+